- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07947914
Urolithin A and Its Effects on Attention and Sleep Timing in Healthcare Workers After Night Shifts
Effects of Urolithin A on Attention and Circadian Rhythm of Sleep in Healthcare Workers After Night Shifts: An Interventional Study
This pilot study will examine whether taking urolithin A helps healthcare workers stay focused after a night shift. It will also look at changes in fatigue, sleepiness, sleep patterns, and the body's internal clock.
The study plans to enroll 40 physicians and nurses aged 24 to 55 who work scheduled night shifts at Henan Provincial People's Hospital. Participants will be assigned by chance, in equal numbers, to take either 1 gram of urolithin A or a matching placebo capsule by mouth once each morning for five consecutive days, starting the day before the night shift. Participants and the study staff who give out the capsules or assess outcomes will not know which group each participant is in. Participants will follow their usual work schedules.
The main measure is the Stroop interference effect, which is the difference in average response time between correct answers when a color word conflicts with its displayed color and correct answers when they match. The researchers will compare how this measure changes from two days before the night shift to the scheduled follow-up assessments in the two groups.
Participants will also rate their fatigue and sleepiness, wear a wrist device to track sleep, keep a sleep diary, and provide saliva samples to measure melatonin. They will complete tasks that measure alertness and the ability to withhold a response during three MRI scans scheduled before the night shift, on the morning the shift ends, and during recovery. The study will help estimate how much the main measure varies among participants to inform a larger trial.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
This single-center, randomized, double-blind, placebo-controlled pilot trial will be conducted at Henan Provincial People's Hospital. After providing written informed consent and completing baseline assessments, participants will be randomly assigned to a study group. An independent team member who is not involved in recruitment, intervention delivery, or outcome assessment will generate the allocation sequence using SAS version 9.4. Coded study products will be dispensed in enrollment order. Group assignments will be kept confidential until the database is locked, except when emergency unblinding is needed for participant safety.
The day on which the scheduled night shift begins is designated Day 0. Baseline assessments will take place on Day -2. Participants will take their assigned study product each morning from Day -1 through Day 3 and will work their usual scheduled night shift. Computerized Stroop testing will be conducted each morning from Day -2 through Day 4 between 07:00 and 09:00. The final assessment will take place on Day 4, after the dosing period has ended.
Task-based functional MRI will be performed at baseline (Day -2), on the morning the night shift ends (Day 1), and during recovery (Day 3). During each scan, participants will complete an 8-minute Psychomotor Vigilance Task and a 6-minute Go/No-Go task. Stimulus timing and button responses will be recorded and synchronized with image acquisition. Wrist activity recordings will be reviewed alongside sleep diaries to distinguish nighttime sleep from daytime naps and identify periods when the device was removed. Saliva will be collected at scheduled times throughout the observation period, with an additional sample at 03:00 during the night shift. Study staff will record actual sample collection times, review dosing and visit records, and document missed doses, concomitant medication use, and adverse events.
Repeated Stroop interference measurements will be analyzed using a linear mixed-effects model with terms for study group, visit, and their interaction, with adjustment for baseline performance and a participant-level random effect. Estimated between-group differences will be reported with 95% confidence intervals. Exploratory analyses will examine whether changes in task-related brain activity are associated with changes in cognitive performance, fatigue, sleepiness, sleep patterns, and salivary melatonin. Visit completion and adherence data will be used to assess the feasibility of the study procedures for a larger trial.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Jie Wang, PhD
- Número de telefone: 0371-65580020
- E-mail: imyangsiyu@163.com
Estude backup de contato
- Nome: Haoxiang Xu
- Número de telefone: 0371-65580020
- E-mail: xhx0227@163.com
Locais de estudo
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Henan Provincial People's Hospital
-
Contato:
- Jie Wang, PhD
- Número de telefone: 0371-65580020
- E-mail: imyangsiyu@163.com
-
Contato:
- Liangkai Chen, PhD
- Número de telefone: 0371-65580020
- E-mail: clk@hust.edu.cn
-
Subinvestigador:
- Haoxiang Xu, Currently pursuing a master's
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged 24 to 55 years, inclusive.
- Physicians or nurses who work scheduled night shifts.
- No history of neurological or psychiatric disorders.
- No diagnosed sleep disorder.
- No contraindications to magnetic resonance imaging (MRI).
- Right-handed.
Exclusion Criteria:
- Recent use of sleep aids or psychoactive medications.
- Severe sleep disruption outside periods of shift work.
- Gastrointestinal disease that may affect urolithin A absorption.
- Pregnancy or breastfeeding.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Urolithin A
Participants will take 1 g of urolithin A(StanYouth™️ Urolithin A) in capsule form by mouth once daily between 07:00 and 09:00 for five consecutive days, from the day before the scheduled night shift (Day -1) through Day 3. |
Oral urolithin A(StanYouth™️ Urolithin A) capsules at a total daily dose of 1 g. The capsules are taken once each morning between 07:00 and 09:00 for five consecutive days, beginning the day before the scheduled night shift (Day -1) and continuing through Day 3. |
|
Comparador de Placebo: Matching Placebo
Participants will take 1 g of matching placebo capsules by mouth once daily between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. The placebo capsules contain no urolithin A and match the urolithin A capsules in appearance, color, and packaging. |
Oral placebo capsules containing no urolithin A and matching the urolithin A capsules in appearance, color, and packaging. The capsules are taken at a total daily dose of 1 g, once each morning between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in the Stroop Reaction Time Interference Effect
Prazo: Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.
|
At each assessment, the Stroop reaction time interference effect is calculated by subtracting the mean reaction time for valid correct responses in congruent trials from the mean reaction time for valid correct responses in incongruent trials. Reaction times are measured in milliseconds. Change from baseline is calculated as the interference effect at each follow-up assessment minus the baseline interference effect. A positive change indicates greater interference than at baseline. |
Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stroop Reaction Time by Trial Condition,Stroop Response Accuracy by Trial Condition
Prazo: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
|
Mean reaction time, in milliseconds, for valid correct responses on the computerized Stroop task, reported separately for congruent and incongruent trials. Percentage of trials with a correct response on the computerized Stroop task, reported separately for congruent and incongruent trials. |
Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
|
|
Psychomotor Vigilance Task
Prazo: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Mean reaction time, in milliseconds, for valid responses. Premature responses and omissions are excluded. Number of responses with a reaction time of at least 500 milliseconds within the 10-second response window. Number of slow responses divided by [prespecified denominator], multiplied by 100. Number of presented targets for which no response is recorded within 10 seconds. Number of omitted responses divided by[ prespecified denominator], multiplied by 100. Number of premature responses, defined as button presses during the waiting interval or responses occurring less than 100 milliseconds after target onset. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
|
Go/No-Go Trial
Prazo: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Mean reaction time, in milliseconds, for correct responses on Go trials. Percentage of presented Go trials with a valid button press within the response window. Percentage of presented Go trials without a valid button press within the response window. Percentage of presented No-Go trials with a button press within the response window. Percentage of presented No-Go trials without a button press within the response window. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
|
Visual Analog Scale for Fatigue Score
Prazo: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
Participants rate their current fatigue on a 100-mm visual analog scale. Scores range from 0 mm (no fatigue) to 100 mm (extreme fatigue), with higher scores indicating greater fatigue. |
Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
|
Karolinska Sleepiness Scale Score
Prazo: Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
Self-rated sleepiness measured on the 9-point Karolinska Sleepiness Scale. Scores range from 1 to 9, with higher scores indicating greater sleepiness. |
Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
|
Fatigue Severity Scale Score
Prazo: Baseline (Day -2) and final follow-up (Day 4).
|
The 9-item Fatigue Severity Scale assesses the impact of fatigue on daily functioning over the past week. Each item is scored from 1 to 7. Item scores are summed to give a total score ranging from 9 to 63, with higher scores indicating a greater impact of fatigue. |
Baseline (Day -2) and final follow-up (Day 4).
|
|
Salivary Melatonin Concentration
Prazo: From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
|
Melatonin concentration measured in saliva samples collected at scheduled times and reported in [laboratory reporting unit]. |
From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
|
|
Actigraphy-Derived Sleep Parameters
Prazo: Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
|
Total time spent asleep during the recorded sleep episode, estimated from wrist actigraphy and reported in minutes. Percentage of time in bed spent asleep, estimated from wrist actigraphy. Time from attempting to fall asleep to estimated sleep onset, reported in minutes. Total time spent awake after initial sleep onset and before final awakening, estimated from wrist actigraphy and reported in minutes. Number of awakenings detected by wrist actigraphy after initial sleep onset and before final awakening. |
Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
|
|
Task-Evoked Brain Activation During the Psychomotor Vigilance Task
Prazo: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Task-evoked brain activation during the Psychomotor Vigilance Task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis]. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
|
Task-Evoked Brain Activation During the Go/No-Go Task
Prazo: Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Task-evoked brain activation during the Go/No-Go task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis]. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Jie Wang, PhD, Henan Provincial People's Hospital
- Diretor de estudo: Liangkai Chen, PhD, Huazhong University of Science and Technology
- Diretor de estudo: Yongli Li, PhD, Henan Provincial People's Hospital
- Diretor de estudo: Zhengqian Li, PhD, Peking University Third Hospital
- Investigador principal: Haoxiang Xu, Currently pursuing a master's, Henan Provincial People's Hospital
Publicações e links úteis
Publicações Gerais
- Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14.
- Ganesan S, Magee M, Stone JE, Mulhall MD, Collins A, Howard ME, Lockley SW, Rajaratnam SMW, Sletten TL. The Impact of Shift Work on Sleep, Alertness and Performance in Healthcare Workers. Sci Rep. 2019 Mar 15;9(1):4635. doi: 10.1038/s41598-019-40914-x.
- Sen A, Tai XY. Sleep Duration and Executive Function in Adults. Curr Neurol Neurosci Rep. 2023 Nov;23(11):801-813. doi: 10.1007/s11910-023-01309-8. Epub 2023 Nov 14.
- Xu N, Du C, Yu Y, Li Y, Gao S, Yu S, Sun B, Lou H. Urolithin A improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity. Exp Neurol. 2025 Nov;393:115395. doi: 10.1016/j.expneurol.2025.115395. Epub 2025 Jul 24.
- Hou Y, Chu X, Park JH, Zhu Q, Hussain M, Li Z, Madsen HB, Yang B, Wei Y, Wang Y, Fang EF, Croteau DL, Bohr VA. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimers Dement. 2024 Jun;20(6):4212-4233. doi: 10.1002/alz.13847. Epub 2024 May 16.
- Xiang J, Xu J, Zhang Y, Liu X. Urolithin A: Potential to enhance autophagic clearance and mitigate neuroinflammation in Alzheimer's disease. Ageing Res Rev. 2026 Jul;119:103157. doi: 10.1016/j.arr.2026.103157. Epub 2026 May 7.
- Song J, Feng P, Wu X, Li B, Su Y, Liu Y, Zheng Y. Individual Differences in the Neural Basis of Response Inhibition After Sleep Deprivation Are Mediated by Chronotype. Front Neurol. 2019 May 15;10:514. doi: 10.3389/fneur.2019.00514. eCollection 2019.
- Yang Z, Williams SD, Beldzik E, Anakwe S, Schimmelpfennig E, Lewis LD. Attentional failures after sleep deprivation are locked to joint neurovascular, pupil and cerebrospinal fluid flow dynamics. Nat Neurosci. 2025 Dec;28(12):2526-2536. doi: 10.1038/s41593-025-02098-8. Epub 2025 Oct 29.
- Bani Issa W, Abdul Rahman H, Albluwi N, Samsudin ABR, Abraham S, Saqan R, Naing L. Morning and evening salivary melatonin, sleepiness and chronotype: A comparative study of nurses on fixed day and rotating night shifts. J Adv Nurs. 2020 Dec;76(12):3372-3384. doi: 10.1111/jan.14530. Epub 2020 Sep 23.
- Choshen-Hillel S, Ishqer A, Mahameed F, Reiter J, Gozal D, Gileles-Hillel A, Berger I. Acute and chronic sleep deprivation in residents: Cognition and stress biomarkers. Med Educ. 2021 Feb;55(2):174-184. doi: 10.1111/medu.14296. Epub 2020 Aug 28.
- Phillips AJK, St Hilaire MA, Barger LK, O'Brien CS, Rahman SA, Landrigan CP, Lockley SW, Czeisler CA, Klerman EB. Predicting neurobehavioral performance of resident physicians in a Randomized Order Safety Trial Evaluating Resident-Physician Schedules (ROSTERS). Sleep Health. 2024 Feb;10(1S):S25-S33. doi: 10.1016/j.sleh.2023.10.018. Epub 2023 Nov 25.
- Williams GW, Shankar B, Klier EM, Chuang AZ, El Marjiya-Villarreal S, Nwokolo OO, Sharma A, Sereno AB. Sensorimotor and executive function slowing in anesthesiology residents after overnight shifts. J Clin Anesth. 2017 Aug;40:110-116. doi: 10.1016/j.jclinane.2017.04.002.
- Basner M, Dinges DF, Shea JA, Small DS, Zhu J, Norton L, Ecker AJ, Novak C, Bellini LM, Volpp KG. Sleep and Alertness in Medical Interns and Residents: An Observational Study on the Role of Extended Shifts. Sleep. 2017 Apr 1;40(4):zsx027. doi: 10.1093/sleep/zsx027.
- Rahman SA, Sullivan JP, Barger LK, St Hilaire MA, O'Brien CS, Stone KL, Phillips AJK, Klerman EB, Qadri S, Wright KP Jr, Halbower AC, Segar JL, McGuire JK, Vitiello MV, de la Iglesia HO, Poynter SE, Yu PL, Sanderson AL, Zee PC, Landrigan CP, Czeisler CA, Lockley SW; ROSTERS STUDY GROUP. Extended Work Shifts and Neurobehavioral Performance in Resident-Physicians. Pediatrics. 2021 Mar;147(3):e2020009936. doi: 10.1542/peds.2020-009936. Epub 2021 Feb 22.
- Mao T, Fang Z, Chai Y, Deng Y, Rao J, Quan P, Goel N, Basner M, Guo B, Dinges DF, Liu J, Detre JA, Rao H. Sleep deprivation attenuates neural responses to outcomes from risky decision-making. Psychophysiology. 2024 Apr;61(4):e14465. doi: 10.1111/psyp.14465. Epub 2023 Oct 31.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 2026-150
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The scope, timing, and access procedures for sharing individual participant data are under consideration. Any future sharing would be limited to de-identified data made available to qualified researchers or research institutions for scientific purposes, subject to ethics committee requirements and applicable regulations.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .